Heartbeam

Heartbeam Financial Leverage

The Financial Leverage (Equity Multiplier) of Heartbeam (BEAT) as of Oct 26, 2026 is 2.24. In the previous year, Financial Leverage (Equity Multiplier) was 1.98 — a change of 13.33% (higher).

Financial Leverage

2.24

YoY

13.33%

Last updated:

Financial Leverage (Equity Multiplier) of Heartbeam is 2025 2.24 . Financial Leverage (Equity Multiplier) of Heartbeam was 2024 1.98 . It decreases by 13.33% higher compared to the previous year.

The Heartbeam Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.89 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
1.04 USD
Jan 1, 2022
1.70 USD
Jan 1, 2023
1.07 USD
Jan 1, 2024
1.98 USD
Jan 1, 2025
2.24 USD
The Heartbeam Financial Leverage history
YEARFinancial LeverageYoY
2.24+13.33%
1.98+84.26%
1.07-36.82%
1.70+62.99%
1.04-9,893.75%
-0.01+467.48%
-0.00-100.10%
1.89-9.65%
2.09+46.04%
1.43-12.39%
1.64-16.56%
1.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Heartbeam Stock analysis

What does Heartbeam do? HeartBeam, Inc. generates revenue through its proprietary VECG technology platform, which includes two patented products: HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software designed for acute care settings, offering 3D comparison of baseline and symptomatic 12-lead ECG to detect heart attacks. HeartBeam AIMIGo is a credit card-sized 12-lead ECG device paired with a smartphone app and cloud-based diagnostic software for remote heart attack detection. The company targets healthcare facilities and remote monitoring segments, focusing on cardiovascular diagnostic solutions for both in-hospital and out-of-hospital settings. HeartBeam AIMI is sold to acute care providers such as hospitals and emergency departments, while HeartBeam AIMIGo serves patients and remote healthcare services seeking continuous cardiac monitoring. The firm's revenue streams derive from the commercialization of these two products, leveraging its patented VECG technology to provide higher resolution ambulatory ECG solutions. The company's focus on detecting and monitoring cardiac disease outside traditional healthcare facilities drives its product development and sales strategy. HeartBeam Inc. operates in the cardiovascular diagnostic technology sector, with its products designed to enable cardiac disease detection both inside and outside healthcare facilities. The firm's VECG platform allows for 3D vector imaging of cardiac electrical activity, enhancing diagnostic capabilities beyond standard ECG methods. Revenue is generated through the sale of software, devices, and cloud-based diagnostic systems tailored to specific healthcare environments and remote monitoring needs. Heartbeam is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Heartbeam stock

Financial Leverage (Equity Multiplier) of Heartbeam is 2.24 in 2025.

Financial Leverage (Equity Multiplier) of Heartbeam changed from 1.98 to 2.24, representing a 13.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Heartbeam since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Heartbeam with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Heartbeam

All Key Metrics — Heartbeam